Vaccine Efficacy
Anti-CD25 antibody enhances vaccine-induced immunogenicity
Published in Hepatitis Weekly, January 30th, 2006
"An efficacious vaccine strategy must be capable of inducing strong responses of an appropriate phenotype that are long lasting and sufficiently broad to prevent pathogen escape mechanisms. In the present study, we use anti-CD25 mAb to augment vaccine-induced immunity in mice. We demonstrate that co-formulation of antibody and poxviral- or adenoviral-vectored vaccines induces significantly increased T cell responses to a malaria antigen; prior anti-CD25 antibody administration was not required for this effect," scientists in the United Kingdom report.
"Furthermore, this vaccination approach...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2006-01-30)
More Articles from Hepatitis Weekly
- Apoptosis
Human hepatitis B virus X protein induces apoptosis in HepG2 cells - Hepatitis B Virus
A noninvasive model predicts significant fibrosis in HBeAg-positive patients - Hepatitis C Vaccine
Researchers in Canada develop dendritic cell-based therapeutic vaccine - Hepatitis C Virus
Interferon-neutralizing antibodies are detectable in chronic hepatitis C - Hepatitis D Virus
Hepatitis B virus replication is inhibited by hammerhead ribozymes - Addiction Medicine
Novel blood markers accurately diagnosis the degree of liver fibrosis - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
